Page 18 - White Paper on Experimental Vaccines for Covid-19*

where we as a company simply cannot take the risk if in ... four years the vaccine is
showing side effects,” Ruud Dobber, a member of Astra’s senior executive team, told
31
Reuters.

7. An Experimental Vaccine Is Not Safer Than a Very Low IFR.
The IFR was always known to be very low for the young and healthy middle aged, and it
has now been shown to be extraordinarily low. We are getting better and better at treating
COVID-19: the death rate in terms of population continues to fall, hospital stays for
COVID-19 get shorter and hospital mortality from COVID-19 plummets.

Questions Regarding the Effectiveness of the COVID-19 Experimental Vaccines

1. No Proof the Vaccine Stops Transmission of the Virus.
The trial data on the vaccinations released so far has not addressed the issue of
transmission of the virus. That is, the efficacy data is primarily based on symptoms, not on
transmission. Could the vaccine create asymptomatic carriers that can unknowingly
transmit the virus? The scientists are very upfront about the fact that they don’t know if the
32
vaccine even stops the spread of the virus! Dr. Corey who oversees the vaccine trials for
the NIH COVID-10 Prevention Network says: “the studies aren’t designed to assess
transmission. They don’t ask that question and there’s really no information on this at this
point in time.”

2. Unknown Mortality or Hospital Admission Benefit.
Currently the pharmaceutical companies believe that their first COVID-19 vaccines are
~95% effective. Pharmaceutical companies typically believe their vaccinations are more
effective than they actually are. For example, CDC data show that the influenza vaccine

31 https://www.reuters.com/article/us-astrazeneca-results-vaccine-liability/astrazeneca-to-be-exempt-
from-coronavirus-vaccine-liability-claims-in-most-countries-idUSKCN24V2EN
32 https://www.medscape.com/viewarticle/941388

16